Loading…
Arcturus Therapeutics Holdings Inc. is projected to rise to $6.16 by 2027, a +7% move from its current price of $5.76. ARCT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 4 | $5.63 | $5.76 | $5.90 | +0.03% |
| Aug 5 | $5.57 | $5.76 | $5.96 | +0.07% |
| Aug 6 | $5.53 | $5.77 | $6.01 | +0.10% |
| Aug 7 | $5.50 | $5.77 | $6.05 | +0.13% |
| Aug 8 | $5.47 | $5.77 | $6.09 | +0.17% |
| Aug 9 | $5.44 | $5.77 | $6.12 | +0.20% |
| Aug 10 | $5.42 | $5.77 | $6.15 | +0.23% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.42 | $5.77 | $6.15 | +0.23% |
| Week 2 | $5.29 | $5.79 | $6.33 | +0.47% |
| Week 3 | $5.20 | $5.80 | $6.47 | +0.70% |
| Week 4 | $5.12 | $5.81 | $6.60 | +0.93% |
| Week 5 | $5.06 | $5.83 | $6.71 | +1.17% |
| Week 6 | $5.00 | $5.84 | $6.82 | +1.40% |
| Week 7 | $4.95 | $5.85 | $6.92 | +1.64% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Arcturus Therapeutics Holdings Inc. is a healthcare company focused on messenger RNA medicines.
Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza.
Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
ARCT is currently trading at $5.93. It holds a market capitalization of $168.55M and ranks 3771 by market size. The stock sits in the Healthcare sector, with versatile mRNA-focused platforms and a pipeline that spans cystic fibrosis, OTC deficiency, and several RNA vaccine/therapy candidates.
The overall price outlook, based on year-by-year forecasts, shows a bullish trajectory later in the horizon. The path from 2026 onward includes rising average prices and higher max targets, with 2030 and beyond projecting meaningful upside relative to the current level. Max forecast values extend to $12.02 in 2030 and up to $49.11 by 2050, reflecting a long-run upward potential despite near-term uncertainty.
A major floor 26.6% below — a decisive break under it would weaken the trend.
The nearest floor, 4.0% below — buyers have tended to step in here.
The nearest ceiling, 31.9% above — a clean break opens room to run.
A major ceiling 60.1% above — clearing it would confirm fresh momentum.
Key ARCT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ARCT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.80 | Sell | $5.81 | Sell |
| MA 10 | $5.82 | Sell | $5.91 | Sell |
| MA 20 | $6.31 | Sell | $6.19 | Sell |
| MA 50 | $6.87 | Sell | $6.76 | Sell |
| MA 100 | $7.40 | Sell | $7.32 | Sell |
| MA 200 | $7.90 | Sell | $8.68 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 34.95 | Neutral |
| Stoch RSI (14) | 76.77 | Neutral |
| CCI (20) | -69.08 | Neutral |
| Williams %R (14) | -73.26 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -9.86 | Sell |
| Bollinger %B (20,2) | 0.28 | Neutral |
| Stochastic %K (14) | 26.74 | Neutral |
| TRIX (15) | -0.76 | Sell |
| Awesome (5,34) | -0.83 | Sell |
| Ultimate (7,14,28) | 35.09 | Neutral |
| Momentum (10) | -0.29 | Sell |
| Aroon Osc (25) | -52.00 | Sell |
| Hull MA (9) | 5.83 | Sell |
| ADX (14) | 26.76 | Sell |
| ATR (14) | 0.15 | Info |
The 30-day technical picture shows a bearish tone in the near term. RSI(14) is 30, indicating modest negative momentum.
The stock’s 50-day simple moving average is $7.15 and the 200-day simple moving average is $8.41, suggesting the price could face resistance near those levels. Support is cited at $5.93, with a resistance at $7.60. Over the last 30 days, the price range has been $5.05 to $6.97, highlighting a relatively narrow trading window.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.53 | $5.76 | $7.39 | 0% | Neutral | |
| $4.97 | $6.16 | $8.04 | +7% | Neutral | |
| $5.69 | $7.23 | $9.75 | +25% | Bullish | |
| $6.57 | $8.52 | $11.81 | +48% | Bullish | |
| $6.21 | $8.20 | $11.61 | +42% | Bullish | |
| $6.16 | $8.26 | $11.92 | +43% | Bullish | |
| $6.57 | $8.95 | $13.14 | +55% | Bullish | |
| $6.70 | $9.24 | $13.79 | +60% | Bullish | |
| $7.83 | $10.95 | $16.58 | +90% | Bullish | |
| $8.43 | $11.93 | $18.31 | +107% | Bullish | |
| $10.78 | $16.15 | $26.21 | +180% | Bullish | |
| $15.93 | $26.27 | $46.30 | +356% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $5.53 | $5.76 | $7.12 | +0.00% |
| September 2026 | $5.16 | $6.08 | $7.35 | +5.59% |
| October 2026 | $5.01 | $5.94 | $7.25 | -2.38% |
| November 2026 | $4.93 | $5.88 | $7.23 | -1.01% |
| December 2026 | $4.99 | $5.97 | $7.39 | +1.52% |
Click any year to see its month-by-month ARCT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ARCT price prediction for 2026 points to an average of $5.76 (low $5.53, high $7.39) — a potential gain of 0% on today's $5.76. A consolidation phase looks the most probable path here.
In 2027, ARCT is projected to trade between $4.97 and $8.04, averaging $6.16 — a potential gain of +7% from today's $5.76. That is up +7% on the projected 2026 average. Price action looks broadly range-bound.
Arcturus Therapeutics Holdings Inc.'s 2028 outlook centres on $7.23, within a $5.69 to $9.75 range. That is up +17% on the projected 2027 average. That marks a +25% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, ARCT could reach as high as $11.81, with a base case around $8.52 and support toward $6.57 — roughly +48% from $5.76. Momentum favours further upside here.
Expect ARCT to range from $6.21 to $11.61 through 2030. The $8.20 average target implies a +42% move from current prices. That is -4% versus the projected 2029 average. Buyers look set to stay in control over this stretch.
The ARCT price prediction for 2031 points to an average of $8.26 (low $6.16, high $11.92) — a potential gain of +43% on today's $5.76. Momentum favours further upside here.
In 2032, ARCT is projected to trade between $6.57 and $13.14, averaging $8.95 — a potential gain of +55% from today's $5.76. That is up +8% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Arcturus Therapeutics Holdings Inc.'s 2033 outlook centres on $9.24, within a $6.70 to $13.79 range. That is up +3% on the projected 2032 average. That marks a +60% change versus current levels. Momentum favours further upside here.
By 2034, ARCT could reach as high as $16.58, with a base case around $10.95 and support toward $7.83 — roughly +90% from $5.76. Buyers look set to stay in control over this stretch.
Expect ARCT to range from $8.43 to $18.31 through 2035. The $11.93 average target implies a +107% move from current prices. That is up +9% on the projected 2034 average. Momentum favours further upside here.
The ARCT price prediction for 2040 points to an average of $16.15 (low $10.78, high $26.21) — a potential gain of +180% on today's $5.76. Buyers look set to stay in control over this stretch.
In 2050, ARCT is projected to trade between $15.93 and $46.30, averaging $26.27 — a potential gain of +356% from today's $5.76. That is up +63% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in ARCT today (≈ 173.611111 ARCT) could be worth
$4,560.6
+$3,560.6 (+356%) by 2050 · US Dollar
Based on the average projected ARCT price of $26.27 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ARCTwould be worth at today's price.
$1,000 invested in ARCT on Jul 31, 2025 (≈ 81.900082 ARCT) would be worth
$471.74
-$528.26 (-52.8%) today · 0.47× · US Dollar
Based on a ARCT entry price of $12.21 vs. today's $5.76.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.53 | $1,041.59 | +4.2% |
| 1 month ago | $6.89 | $835.99 | -16.4% |
| 3 months ago | $8.63 | $667.44 | -33.3% |
| 6 months ago | $7.37 | $781.55 | -21.8% |
| 1 year ago | $12.21 | $471.74 | -52.8% |
| All time (5.0y) ago | $44.76 | $128.69 | -87.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ARCT forecast.
Our base-case forecast reaches $12.00 around 2040.
Implied market cap at $12.00: $341.08M
The multi-year forecast shows a bullish trajectory with a clear upstep in value from 2026 to 2050. In 2026 the min is $5.93, avg $5.93, max $7.64 with ROI 0 and NEUTRAL sentiment. In 2027 the min is $5.12, avg $6.36, max $8.33 with ROI 7.2 and NEUTRAL sentiment.
In 2028 the min is $5.97, avg $7.61, max $10.32 with ROI 28.4 and BULLISH sentiment, followed by 2029 with min $6.84, avg $8.90, max $12.39 and ROI 50.1.
2030 shows further gains with min $6.38, avg $8.45, max $12.02 and ROI 42.5; 2031 min $6.43, avg $8.66, max $12.57 and ROI 46.1; 2032 min $6.89, avg $9.42, max $13.91 and ROI 58.8; 2033 min $6.92, avg $9.60, max $14.40 and ROI 61.8; 2034 min $8.24, avg $11.58, max $17.64 and ROI 95.3; 2035 min $8.87, avg $12.63, max $19.49 and ROI 112.9. By 2040 the forecast shows min $11.48, avg $17.33, max $28.33 and ROI 192.3 with BULLISH sentiment; by 2050 min $16.57, avg $27.63, max $49.11 and ROI 366 with BULLISH sentiment.
These figures illustrate a long-run upside potential, but they are estimates, not guarantees, and actual results may differ. Investors should consider the potential for volatility and the inherent uncertainty in multi-year forecasts.
Tap a question to reveal the answer.
Avg $8.45; min $6.38; max $12.02; ROI 42.5; sentiment BULLISH.
Forecasts show a bullish path from 2028 onward with ROI values of 28.4 (2028), 50.1 (2029), 42.5 (2030), 46.1 (2031), 58.8 (2032), 61.8 (2033), 95.3 (2034), 112.9 (2035), 192.3 (2040), and 366 (2050), alongside rising average prices.
2035 max $19.49; 2040 max $28.33; 2050 max $49.11. The max forecast crosses $20 by 2040.
Current price $5.93; Market cap $168.55M.
Sentiment BEARISH; RSI14 30; SMA50 $7.15; SMA200 $8.41; 30-day range $5.05-$6.97; Support $5.93; Resistance $7.60.
Arcturus Therapeutics Holdings Inc. Community Discussion
0Share your Arcturus Therapeutics Holdings Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.